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Abstract: The effectiveness of hematopoietic stem cell transplantation (HSCT) for type-VII
mucopolysaccharidosis (MPS VII, Sly syndrome) remains controversial, although recent studies have
shown that it has a clinical impact. In 1998, Yamada et al. reported the first patient with MPS VII,
who underwent HSCT at 12 years of age. Here, we report the results of a 22-year follow-up of that
patient post-HSCT, who harbored the p.Ala619Val mutation associated with an attenuated phenotype.
The purpose of this study was to evaluate changes in physical symptoms, the activity of daily living
(ADL), and the intellectual status in the 34-year-old female MPS VII patient post-HSCT, and to prove
the long-term effects of HSCT in MPS VII. Twenty-two years after HSCT, the β-glucuronidase activity
in leukocytes remained at normal levels, and urinary glycosaminoglycan excretion was reduced
and kept within normal levels. At present, she is capable of sustaining simple conversation, and
her intellectual level is equivalent to that of a 6-year-old. She can walk alone and climb upstairs by
holding onto a handrail, although she feels mild pain in the hip joint. The cervical vertebrae are fused
with the occipital bone, causing dizziness and light-headedness when the neck is bent back. Overall,
her clinical condition has been stabilized and kept well for long-term post-HSCT, indicating that
HSCT is a therapeutic option for MPS VII.
Keywords: mucopolysaccharidoses; Sly syndrome; activity of daily living; hematopoietic stem
cell transplantation
1. Introduction
Mucopolysaccharidosis VII (MPS VII; Sly syndrome; OMIN#253220) is an autosomal recessive
lysosomal storage disorder (LSD) that is caused by a deficiency of the activity of β-glucuronidase
(GUSB: β-d-glucuronoside Enzyme Commission (EC) number: 3.2.1.31; GUSB: MIM611499)[1,2].
The deficiency of this enzyme leads to the accumulation of specific glycosaminoglycans (GAGs),
i.e., chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS). This disease was first
clinically described by Sly et al. in a patient whose features were similar to those of the patient described
here [1]. Although clinical phenotypes are widely seen from the most severe phenotype with hydrops
fetalis to the attenuated phenotype without central nervous system (CNS) involvement, patients with
MPS VII often show short stature, hepatosplenomegaly, progressive skeletal deformities of the thorax
and spine, and frequent symptomatic pulmonary infections before 2 years of age. Intellectual disability
also appears at 2 years of age. Montaño et al. reported that 34% of patients were diagnosed prenatally
Diagnostics 2020, 10, 105; doi:10.3390/diagnostics10020105 www.mdpi.com/journal/diagnostics
Diagnostics 2020, 10, 105 2 of 8
or below 1 year of age, 16% from 1 year to 3 years of age, 11% from 3 years to 5 years of age, 20% from
5 years to 10 years of age, and 12% over 10 years of age [3]. Thirteen patients with MPS VII who had
the infantile form with a history of hydrops fetalis and survived childhood showed various clinical
manifestations from mild to severe [3]. Radiologic changes of “dysostosis multiplex” involve the
skull, spine, ribs, and long and short tubular bones. MPS VII patients with the most severe phenotype
have hydrops fetalis at birth and often do not survive more than a few months. Patients with mild
manifestations of MPS VII have survived into the fifth decade of life. Fifty-eight different pathogenic
mutations in the GUSB gene have been identified to date [4]. A genotype/phenotype analysis indicated
that the more severe phenotype was associated with truncating mutations.
At present, two therapeutic options are available: enzyme replacement therapy (ERT) and
hematopoietic stem cell transplantation (HSCT). For ERT, a recombinant form of human GUS
(vestronidase alpha) has been recently developed and used successfully [5], giving rise to a reduction
of urinary GAGs and an improvement of the organomegaly [6]. However, the intravenously injected
rhGUS does not cross the blood-brain-barrier and provides no effect on neurological signs, while HSCT
can bring the enzyme into the brain via its secretion from donor-derived microglial cells and prevent or
slow the neurological deterioration [7]. As learned from other MPS types, HSCT should be performed
at an early stage of these diseases in the absence of pre-existing neurological damage. To date, several
institutes have encountered HSCT in MPS VII patients. Although benefits in MPS VII treated with
HSCT have been observed regarding the somatic features of the disease, the impact on cognitive
function remains uncertain because of a lack of long-term observation of neurocognitive benefit.
We previously reported the first HSCT case with MPS VII with 2 years of follow-up post-HSCT
after the patient underwent HSCT at 12 years of age [8]. Here we have followed up this patient
over 20 years post-HSCT, and evaluated the clinical condition, including physical activity and
neurocognitive function.
2. Case Report
2.1. Diagnosis
Informed consent was obtained from her guardians. The study was approved by the ethics
committee on human research at Gifu University (IRB number; 24-176, and 26-411) and followed the
ethical principles of the Declaration of Helsinki. The patient was born at a gestational age of 38 weeks
from an uncomplicated first pregnancy of related parents, weighing 2800 g (+0.28 standard deviation
(SD)), birth length of 47.2 cm (−0.45 SD), and a head circumference of 33.4 cm (+0.29 SD). She had coarse
facial features, hepatosplenomegaly, umbilical herniation, peripheral pulmonary stenosis, ventricular
septal defect, severe neonatal jaundice, and abnormal peripheral leukocytes with striking coarse
metachromatic granules. The diagnosis was established at the age of 1 month by the demonstration of
a pronounced increase in the excretion of the urinary DS and CS and deficiency of β-glucuronidase in
leukocytes. At 6 years of age, Tomatsu et al. identified the mutation in her β-glucuronidase cDNA
producing the p.Ala619Val substitution [9]. She suffered from recurrent acute otitis media starting at
several months of age, and mild deafness was first recognized at the age of 5 years. Developmental
delay was noticed at 3 years of age, after which intellectual disability progressed gradually. Bone
deformities (lumbar gibbus, bilateral femoral caput hypoplasia) worsened steadily. She became
wheel-chair bound at 10 years of age because of gait disturbances, hip pain, and shortness of breath.
Her grasp weakened until she could not lift her handbag. She suffered recurrent upper respiratory tract
and middle ear infections. To attempt to reverse her progressive neurologic and somatic deterioration,
the parents requested that a HSCT be considered [9].
2.2. Hematopoietic Stem Cell Transplantation (HSCT)
At the age of 12 years, the patient received a successful allogeneic HSCT, from an HLA-identical,
unrelated female to correct the enzyme deficiency. The patient had full engraftment. Within 5 months
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after HSCT, the enzyme activity of the recipient’s lymphocytes increased to the normal range. No sign
of acute or chronic GVHD was observed. For the successive 31 months, β-glucuronidase activity in her
leukocytes rose to nearly normal levels, and the excretion of urinary GAGs was greatly diminished
and normalized [8].
2.3. Clinical Course after HSCT
Clinical improvement, including motor function, was well recognized. The patient became
ambulatory without aid and could even ride a bicycle and bathe alone. The recurrent infections of
the upper respiratory tract and the middle ears decreased in frequency and severity, and dyspnea on
exertion, snoring, and vertigo improved substantially [8]. At 12 years of age pre-HSCT, her intelligence
quotient (IQ) was 50, i.e., the equivalent to the developmental level of a 6-year-old, but dropped from
50 to 47 two years after the HSCT [8] (Table 1).
Table 1. Clinical manifestations.
5 Months before HSCT 15 Months after HSCT 17 Years after HSCT 21 Years after HSCT
age 12y2m 13y10m 29y11m 34y2m
Height (cm) 141.5(−1.4 SD)
141.5
(−2.6 SD)
144.2
(−2.6 SD)
143.8
(−2.7 SD)
Weight (kg) 47.0(+0.5 SD)
41.3
(−0.9 SD)
53.6
(+0.1 SD)
54.3
(+0.2 SD)
Body mass index 23.5 20.6 25.8 26.3
Intelligence
quotient 50 47 37 37
Coarse facies coarse coarse coarse coarse
Corneal clouding normal normal normal normal
Thoracolumbar
gibbus abnormal abnormal abnormal abnormal
Bone deformity abnormal abnormal abnormal abnormal
Hepatosplenomegaly none none none none
Snoring severe diminished diminished diminished
Deafness moderate moderate moderate moderate
Heart disease Moderate MRModerate AR
Moderate MR
Moderate AR
Moderate MR
Moderate AR
Moderate MR
Moderate AR
Walking Wheelchair Ambulatory Ambulatory Ambulatory
SD: standard deviation, MR: mitral valve regurgitation, AR: aortic valve regurgitation.
At 29 years of age (17 years after HSCT), her IQ (Tanaka-Binet intelligence test V) dropped from
50 to 37 before and after HSCT (Table 1). She could walk 360 m alone in a 6 min-walk test. She has not
suffered from upper respiratory infections for several years. She couldn’t calculate change for shopping
by herself. She showed mild scoliosis, mild left ventricle hypertrophy, and moderate aortic valve
regurgitation (Table 1). Ophthalmologic examination revealed no abnormalities in the cornea or retina.
In the otolaryngological examination, tubing was inserted into the eardrum, and hearing tests showed
moderate right-sided hearing loss and left-sided mixed hearing loss, respectively. The orthopedic
assessment showed instability of the cervical spine and limited range of motion of the hip joint.
The brain MRI showed no significant difference compared with that at pre-HSCT. β-glucuronidase
activity in leukocytes was normal (Table 2). Excreted GAGs in urine were normal (Table 3).
At 34 years of age (22 years after HSCT), her IQ (Tanaka-Binet intelligence test V) was 37, i.e.,
the same as at the age of 29. She can have a simple conversation but cannot calculate change for
shopping. She retained her ambulatory mobility well. She sometimes experiences hip pain, but she
can walk alone and climb upstairs using handrails. She may feel dizzy or lightheaded when tilting
her head backward when looking up. Ophthalmologic examination revealed no abnormalities in the
cornea or retina. In the otolaryngological examination, tubing was inserted into the eardrum. Hearing
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tests showed moderate right-sided hearing loss and left-sided mixed hearing loss, respectively; hearing
loss on the left side was slightly lower than four years ago. Numbness and wobbling were observed
during the rotation of the neck. In orthopedic assessment, the range of motion of the hip joint was
limited but remained unchanged. Her respiratory function showed mild restricted impairment with a
vital capacity (VC) of 69% and a forced expiratory volume/second (FEV1.0) of 1.5. Echocardiography
showed moderate aortic regurgitation and mitral regurgitation, but cardiac function was not worsened
compared with the findings at 29 years of age.
Table 2. β-glucuronidase activity in lymphocytes before and after HSCT.
before HSCT 17 Years after HSCT Control
β-glucuronidase
(nmol/mg protein/h) ND 144.5 116.4–240.4
Arylsulfatase
(nmol/mg protein/h) NT 132.4 109.0–217.2
β-hexosaminidase
(nmol/mg protein/h) 1427 NT 562–882
ND: not detected, NT: not tested.
Table 3. Urinary GAGs excretion before and after HSCT.
5 Months before HSCT 15 Months after HSCT 17 Years after HSCT
Urinary GAGs
(mg/g creatinine) 44.0 18.0 12.1
Control 14.2 ± 6.8 11.7 ± 5.7 10.3 ± 2.0
2.4. Radiological Findings
An X-ray of the hip revealed dysplasia of the hip acetabulum and deformation of the femoral head
at age of 9, 15, and 29, respectively (Figure 1). Although there was no apparent progression with age, it
was considered to be the cause of the limitation of the range of motion of the hip joint and hip pain.
Cervical spine CT at 29 years old showed the occipitalization of atlas (also known as atlanto-occipital
assimilation) that the first cervical vertebra was fused with the occipital bone at some sites (Figure 2).
No obvious atlantoaxial subluxation was found. Brain MRI at the age of 34, i.e., 22 years after HSCT,
showed no abnormal findings, e.g., atrophy of the cerebral cortex, ventricular enlargement, or cyst
formation. (Figure 3).
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Figure 1. X-ray of the pelvis (A) pelvis at 9 years old, 3 years before HSCT, (B) pelvis at 15 years old,
3 years post-HSCT, (C) pelvis at 29 years old, 17 years post-HSCT. Dysplasia of the hip acetabulum
(black arrow) and deformation of the femoral head (white arrow) are observed. No obvious narrowing
of the joint space has been seen.
Diagnostics 2020, 10, 105 5 of 8
Diagnostics 2020, 10, x FOR PEER REVIEW 5 of 8 
 
 
Figure 2. Cervical spine CT at 29 years old. Occipitalization of Atlas is seen. (A) Sagittal section. 
Occipitalization of the anterior arch of the first cervical vertebra and the lower surface of the occipital 
bone at the part indicated by the white arrow. (B) sagittal section and (C) coronal section. 
Occipitalzation of the lateral mass of the first cervical vertebra and the lower surface of the occipital 
bone are fused at the area indicated by the white arrow. 
 
Figure 3. Brain MRI at 34 years of age (22 years post-HSCT). (A) Sagittal T1-weighted image. (B) Axial 
T2-weighted image. The white dotted line indicates the level of axial T2-weighted image shown in 
(B). 
3. Discussion 
ERT is routinely and successfully used in patients with several types of MPS [7]. ERT using a 
recombinant human GUS enzyme, vestronidase alfa, was approved by the FDA and EMA in 2019. 
Regarding MPS VII, Fox et al. reported the use of the successful ERT in a 12-year-old boy with 
advanced MPS VII [6]. 
A pivotal phase-III trial on vestronidase alfa has shown a significant decrease in urinary CS-DS 
excretion after 24 weeks [5]. While a marked amelioration of organomegaly and fatigue was observed, 
only a relative improvement in the mobility and the respiratory functions was noted [5]. The 
recombinant enzyme is directly infused into the bloodstream allowing its delivery to peripheral 
organs except for the brain, because of its inability to cross the blood-brain barrier. To improve or 
prevent any potential neurological impairment, the application of HSCT should be considered. HSCT 
is based on the supply of deficient enzymes through nondeficient GUS-producing hematopoietic cells 
and its derivatives like brain microglia [10]. To date, 10 cases treated with HSCT have been reported 
Figure 2. Cervical spine CT at 29 years old. O cipitalization of Atlas is seen. (A) Sagittal section.
O cipitalization of the anterior arch of the first cervical vertebra and the lower surface of the o cipital
bone t the part ind cated by the white arrow. (B) sagittal section nd (C) coronal section. Occipitalzation
of the lateral mass of the first cervical v rtebra and the lower surface of the occipit l b ne are fused at
the area indicated by the white arrow.
Diagnostics 2020, 10, x FOR PEER REVIEW 5 of 8 
 
 
Figure 2. Cervical spine CT at 29 years old. Occipitalization of Atlas is seen. (A) Sagittal section. 
Occipitalization of the anterior arch of the first cervical vertebra and the lower surface of the occipital 
bone at the part indicated by the white arrow. (B) sagittal section and (C) coronal section. 
Occipitalzation of the lateral mass of the first cervical vertebra and the lower surface of the occipital 
bone are fused at the area indicated by the white arrow. 
 
Figure 3. Brain MRI at 34 years of age (22 years post-HSCT). (A) Sagittal T1-weighted image. (B) Axial 
T2-weighted image. The white dotted line indicates the level of axial T2-weighted image shown in 
(B). 
3. Discussion 
ERT is routinely and successfully used in patients with several types of MPS [7]. ERT using a 
recombinant human GUS enzyme, vestroni ase alfa, was appro ed by the FDA and EMA in 2019. 
Regarding MPS VII, Fox et al. reported the use of the successful ERT in a 12-year-old boy with 
advanced MPS VII [6]. 
A pivotal phase-III trial on vestronidase alfa has shown a significant decrease in urinary CS-DS 
excretion after 24 weeks [5]. While a marked amelioration of organomegaly and fatigue was observed, 
only a relative improvement in the mobility and the respiratory functio s was noted [5]. The 
recombinant enzy e is directly infused into the bloodstream allowing its delivery to peripheral 
organs except for the brain, because of its i ability to cross the blood-brain barrier. To improve or 
preve t any otential neurological impairme t, the application of HSCT should be considered. HSCT 
is based on the supply of deficient enzymes through nondeficie t GUS-producing hematopoietic cells 
and its erivatives like brain microglia [10]. To date, 10 cases treated with HSCT have been reported 
Figure 3. Brain MRI at 34 years of age (22 years post-HSCT). (A) Sagittal T1-weighted image. (B) Axial
T2-weighted image. The white dotted line indicates the level of axial T2-weighted image shown in (B).
3. Discussion
ERT is routinely and successfully used in patients with several types of MPS [7]. ERT using a
recombinant human GUS enzyme, vestronidase alfa, was approved by the FDA and EMA in 2019.
Regarding MPS VII, Fox et al. reported the use of the successful ERT in a 12-year-old boy with advanced
MPS VII [6].
A pivotal phase-III trial on estr i ase alfa has shown a significant decrease in urinary
CS-DS excretion after 24 weeks [5]. While a marked amelioration of organomegaly and fatigue
was observed, only a relative improvement in the mobility and the respiratory functions was noted [5].
The recombinant enzyme is directly infused into the bloodstream allowing its delivery to peripheral
organs except for the brain, because of its inability to cross the blood-brain barrier. To improve or
prevent any potential neurological impairment, the application of HSCT should be considered. HSCT
is based on the supply of deficient enzymes through nondeficient GUS-producing hemato oietic cells
and its derivatives like brain microglia [10]. To date, 10 cases treated with HSCT have been re orted in
patie ts with MPS VII [3,8,11–14]; two of them underwent HSCT at a later stage, i.e., 7 and 12 years
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of age [3]. One patient was of unknown age, while the remaining seven underwent HSCT before 4
years of age [3,11–14]. Three of the nine patients died within a few years after HSCT [3,12]. Five of the
seven surviving cases were reported within three years after HSCT [3,8,11,14]. It was thought that
neurological development was often well maintained in patients who had no neurological symptoms
at 3 years of age and who underwent HSCT before that time. In patients with neurological symptoms
at 3 years of age, neurological development after HSCT was not improved but was maintained at the
same or at a mildly reduced level.
Two long-term follow-up reports after HSCT were reported [3,13]. The case of transplantation
at 2 years of age and retransplantation at the age of three and a half years had scoliosis but proper
neurological development for six years [13]. The case transplanted at 3 years of age showed moderate
physical and neurological symptoms; however, the symptoms had been maintained for 12 years [3].
In this study, we have described the long-term course of the patient who received the first HSCT in
MPS VII [8]. She underwent HSCT at the age of 12 years since she had moderate intellectual disability
and difficulty walking, became wheelchair-bound, and had reduced motor skills. Two years after
HSCT, she could walk again with the improvement of physical activity and ADL. Snoring was reduced,
and respiratory function tests showed mild restrictive disorders which were maintained without
deterioration. Her intellectual level decreased but was maintained for over 20 years post-HSCT. At the
age of 12 years before HSCT, her IQ was 50, which was considered a developmental stage equivalent
to that of a 6-year-old. Twenty-two years after HSCT, her IQ had dropped from 50 to 37. Although she
did not show any improvement in development, she could live at a stage of development comparable
to that of 6-year-old, with no loss of ability gained before and after HSCT. Twenty-two years after
HSCT, changes in physical symptoms were observed due to the fusion of the first cervical vertebra and
occipital bone, worsening of cervical vertebra instability, progression of degeneration of the hip joint,
and mild deterioration of hearing.
Tomatsu and coworkers described some genotype-phenotype correlations [15]. Our patient
harbored the p.Ala619Val mutation associated with an attenuated phenotype [15]. The p.Ala619Val
mutation is of great interest since it is specific to the Japanese population [15]. The p.Ala619Val mutation
expressed 9.1% of normal cDNA in transfected COS cells. The residual activity of these expressed
mutant proteins correlated with the attenuated phenotype for those mutations [15]. Cross-Sectional
analysis showed that a higher residual β-glucuronidase enzyme activity in fibroblasts and lower GAGs
excretion in urine were associated with longer survival [16]. Another Japanese patient with MPS VII
with the p.ALa619Val mutation was diagnosed at the age of 24, but started walking at 2 years of age,
had surgery for inguinal hernia at 4 years of age, and had mild gait disturbance [8]. At the age of 14,
he had an IQ of 66 and a short stature, i.e., 125.2 cm (−5.5 SD). Until he was 30 years old, he was able to
ride a bicycle and did not experience any deterioration in his athletic ability. In MPS VII, the correlation
between genotype and phenotype has been reported [15], and p.Ala619Val is considered an attenuated
type. From the comparison of these two cases, it was considered that among the attenuated types of
p.Ala619Val, the symptoms varied among the patients. In this case, the improvement of motor function
was observed by HSCT starting even at 12 years of age, although the slow progression of neurological
findings might be due to the p.Ala619Val mutation.
Occipitalzation of the atlas is thought to be a manifestation of the so-called occipital vertebrae
(that is, incomplete segmentation between the atlantal and occipital bone) [17]. Occipitalzation of the
atlas is caused by the failure of the segmentation between the fourth occipital sclerotome (proatlas)
and the first cervical sclerotome during embryonic development [18]. The incidence of occipitalization
of the atlas ranges from 0.08% to 2.76% [19]. Occipitalization of the atlas and MPS VII may have been
merged, but the careful follow-up was necessary due to increased instability of the cervical spine.
In conclusion, the current long-term observation post-HSCT in an MPS VII patient has
demonstrated that HSCT has a therapeutic impact on motor function and ADL, and should be
considered as a therapeutic option.
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It is critical that a well-trained medical team and facility provide multi-disciplinary care with
the accompanying changes in skeletal dysplasia, hearing, visual acuity, cognitive function, ADL,
respiratory function, sleep apnea, and p valvular heart disease.
To provide further improvement in the long-term prognoses of MPS VII patients, early diagnosis
and treatment of ERT or HSCT are essential.
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Abbreviations
HSCT Hematopoietic stem cell transplantation
MPS VII Mucopolysaccharidosis type VII (Sly syndrome)
ADL Activity of living
GAGs Glycosaminoglycans
DS Dermatan sulfate
HS Heparan sulfate
CS Chondroitin sulfate
LSD Lysosomal storage disorder
CNS Central nervous system
GUS Glucuronidase
rhGUS Recombinant human glucuronidase
ERT Enzyme replacement therapy
MRI Magnetic resonance imaging
IQ Intelligence quotient
SD Standard deviation
MR Mitral valve regurgitation
AR Aortic valve regurgitation
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